{"url_path":"/sec/vivs/10-k/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-07-14","source_url":"https://www.sec.gov/Archives/edgar/data/1497253/0001193125-26-303316-index.html","accession_number":"0001193125-26-303316","cik":"0001497253","ticker":"VIVS","issuer_name":"VivoSim Labs, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1497253/0001193125-26-303316-index.html","primary_entity_key":"0001497253","primary_entity_name":"VivoSim Labs, INC."},"word_count":714,"has_tables":true,"body_markdown":"10-K\n\n0001497253FYfalseP1Yhttp://fasb.org/us-gaap/2025#FairValueInputsLevel3Member2024-03http://www.vivosim.ai/20260331#ExecutiveChairmanMember0001497253vivs:TwoThousandTwentySixOfferingMemberus-gaap:SubsequentEventMember2026-04-012026-04-010001497253vivs:CommonStockWarrantMemberus-gaap:MeasurementInputExpectedTermMember2026-03-310001497253vivs:ClemsonUniversityMember2024-04-012025-03-310001497253us-gaap:AdditionalPaidInCapitalMember2025-03-3100014972532025-03-252025-03-250001497253vivs:PlacementAgentWarrantsMember2025-03-310001497253vivs:TwoThousandEighteenSalesAgreementMember2025-04-012026-03-310001497253vivs:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember2024-04-012025-03-310001497253vivs:CommonStockWarrantMemberus-gaap:MeasurementInputSharePriceMember2026-03-310001497253vivs:BICOGroupABMembervivs:SalesBasedRoyaltiesMember2025-04-012026-03-310001497253us-gaap:CommonStockMember2024-04-012025-03-310001497253vivs:EquityIncentivePlanTwoThousandTwentyTwoMember2026-03-310001497253us-gaap:TreasuryStockCommonMember2024-04-012025-03-310001497253vivs:TwoThousandTwentySixOfferingMembervivs:TwoThousandTwentySixCommonWarrantsMembersrt:MaximumMember2026-03-310001497253us-gaap:ResearchAndDevelopmentExpenseMember2025-04-012026-03-310001497253vivs:TwoThousandTwentySixOfferingMembervivs:JosephGunnarCoLLCMember2024-05-082024-05-080001497253vivs:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember2023-10-310001497253vivs:TwoThousandTwentySixPre-FundedWarrantsMember2025-03-310001497253vivs:CommonWarrantsMember2026-03-310001497253us-gaap:RetainedEarningsMember2024-04-012025-03-310001497253us-gaap:MeasurementInputPriceVolatilityMembervivs:CommonStockWarrantMember2026-03-3100014972532025-09-012025-09-300001497253vivs:AtTheMarketFacilityMember2026-03-310001497253us-gaap:OperatingSegmentsMember2025-04-012026-03-310001497253us-gaap:CommonStockMembervivs:CommonWarrantsMembervivs:TwoThousandTwentySixOfferingMembersrt:MaximumMember2026-03-3100014972532025-04-012026-03-310001497253vivs:TwoThousandAndTwentySixCommonWarrantsMember2026-03-310001497253us-gaap:EmployeeStockOptionMembervivs:TwoThousandAndTwentyOneInducementEquityPlanMember2026-03-310001497253vivs:TwoThousandTwentySixOfferingMembervivs:Pre-FundedWarrantsMember2026-03-312026-03-310001497253vivs:InducementAwardAgreementsMember2022-02-280001497253us-gaap:MeasurementInputExpectedDividendRateMembervivs:CommonStockWarrantMember2026-03-310001497253us-gaap:MeasurementInputRiskFreeInterestRateMembervivs:PlacementAgentWarrantsMember2026-03-310001497253us-gaap:TreasuryStockCommonMember2026-03-310001497253vivs:CommonWarrantsMembervivs:TwoThousandTwentySixOfferingMembersrt:MaximumMember2026-03-312026-03-310001497253vivs:SanDiegoPermanentLeaseMember2020-11-232020-11-230001497253vivs:TwoThousandTwentySixOfferingMembervivs:PlacementAgentWarrantsMember2026-03-312026-03-310001497253vivs:EquityIncentivePlanTwoThousandTwentyTwoMember2022-10-120001497253us-gaap:EmployeeStockOptionMembervivs:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember2026-03-310001497253srt:MaximumMember2026-03-310001497253vivs:ProspectusToTwoThousandAndTwentyFourShelfMembervivs:AtTheMarketFacilityMembersrt:MaximumMember2025-02-260001497253vivs:TwoThousandTwentySixOfferingMember2026-03-310001497253vivs:ProspectusToTwoThousandAndTwentyFourShelfMembervivs:AtTheMarketFacilityMembersrt:MaximumMember2025-04-1100014972532021-12-170001497253vivs:TwoThousandAndTwentySixCommonWarrantsMember2025-04-012026-03-310001497253vivs:MetacrinesFxrProgramMemberus-gaap:SubsequentEventMember2026-07-012026-07-310001497253us-gaap:CommonStockMember2025-04-012026-03-310001497253vivs:CommonStockWarrantMember2025-04-012026-03-310001497253vivs:InsurancePremiumFinancingLiabilityMember2025-09-012025-09-300001497253vivs:ESPPSharesMember2024-04-012025-03-310001497253us-gaap:EmployeeStockOptionMember2025-04-012026-03-310001497253us-gaap:CommonStockMembervivs:CommonWarrantsMembervivs:TwoThousandTwentySixOfferingMember2026-03-310001497253vivs:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember2023-04-012024-03-310001497253us-gaap:CommonStockMember2024-03-310001497253vivs:TwoThousandTwentySixOfferingMembervivs:Pre-FundedWarrantsMember2026-03-310001497253us-gaap:OperatingSegmentsMemberus-gaap:ProductMember2024-04-012025-03-310001497253vivs:EquityIncentivePlanTwoThousandTwentyTwoMembervivs:ExecutiveChairmanMembervivs:VestingCriteriaBasedOnAchievingCumulativeRevenueMember2024-08-052024-08-050001497253srt:MinimumMember2026-03-310001497253vivs:PlacementAgentWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2026-03-310001497253vivs:TwoThousandAndTwentyFourCommonWarrantsMember2026-03-310001497253us-gaap:DomesticCountryMembersrt:MaximumMember2025-04-012026-03-310001497253us-gaap:OperatingSegmentsMemberus-gaap:RoyaltyMember2025-04-012026-03-310001497253vivs:EquityIncentivePlanTwoThousandTwentyTwoMembervivs:ExecutiveChairmanMembervivs:VestingCriteriaBasedOnDefinitiveAgreementMember2024-08-052024-08-050001497253vivs:EquityIncentivePlanTwoThousandTwentyTwoMember2025-04-012026-03-310001497253us-gaap:OperatingSegmentsMemberus-gaap:RoyaltyMember2024-04-012025-03-310001497253us-gaap:TreasuryStockCommonMember2025-04-012026-03-310001497253us-gaap:RoyaltyMember2024-04-012025-03-310001497253srt:MinimumMember2025-04-012026-03-310001497253vivs:CommonStockWarrantMember2025-03-310001497253us-gaap:AdditionalPaidInCapitalMember2026-03-3100014972532024-04-012025-03-310001497253vivs:ViscientBiosciencesMember2025-03-310001497253vivs:EquityIncentivePlanTwoThousandTwentyTwoMemberus-gaap:CommonStockMembersrt:MaximumMember2022-10-1200014972532024-03-310001497253vivs:EquityIncentivePlanTwoThousandTwelveMember2022-10-1200014972532024-09-300001497253us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012025-03-310001497253vivs:SanDiegoPermanentLeaseMember2020-11-230001497253vivs:AtTheMarketFacilityMember2025-04-012026-03-310001497253us-gaap:AccruedLiabilitiesMember2026-03-310001497253vivs:PreFundedWarrantMember2026-03-310001497253vivs:EquityIncentivePlanTwoThousandTwentyTwoMembervivs:ExecutiveChairmanMemberus-gaap:EmployeeStockOptionMember2024-08-052024-08-050001497253vivs:AtTheMarketFacilityMembersrt:MaximumMembervivs:ProspectusTo2021ShelfMember2021-01-290001497253vivs:TwoThousandTwentySixOfferingMember2026-03-312026-03-3100014972532026-07-1000014972532025-03-310001497253us-gaap:RestrictedStockUnitsRSUMember2025-03-310001497253vivs:CommonWarrantsMembervivs:TwoThousandTwentySixOfferingMember2026-03-310001497253vivs:EquityIncentivePlanTwoThousandTwelveMember2018-07-310001497253us-gaap:DomesticCountryMember2026-03-310001497253us-gaap:MeasurementInputPriceVolatilityMembervivs:PlacementAgentWarrantsMember2026-03-310001497253vivs:TwoThousandAndTwentyFourShelfMember2024-01-260001497253vivs:EquityIncentivePlanTwoThousandTwelveMember2022-07-252022-10-120001497253vivs:TwoThousandAndTwentySixCommonWarrantsMember2026-03-312026-03-310001497253vivs:BICOGroupABMember2022-02-222022-02-220001497253vivs:EquityIncentivePlanTwoThousandTwelveMember2012-01-310001497253vivs:PreFundedWarrantMembervivs:TwoThousandTwentySixOfferingMember2026-03-310001497253us-gaap:EmployeeStockOptionMembervivs:EquityIncentivePlanTwoThousandTwelveMember2026-03-310001497253us-gaap:OperatingSegmentsMemberus-gaap:ProductMember2025-04-012026-03-310001497253us-gaap:CommonStockMember2026-03-310001497253us-gaap:PerformanceSharesMember2024-08-0500014972532025-01-012025-03-310001497253us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-04-012025-03-310001497253vivs:ProspectusToTwoThousandAndTwentyFourShelfMembervivs:AtTheMarketFacilityMember2025-04-012026-03-310001497253vivs:TwoThousandAndTwentyFourPre-FundedWarrantAndAccompanyingTwoThousandTwentySixCommonWarrantMember2024-08-050001497253vivs:TwoThousandAndTwentyFourCommonWarrantsMember2025-03-310001497253vivs:TwoThousandTwentySixPre-FundedWarrantsMembervivs:TwoThousandTwentySixOfferingMember2026-03-312026-03-310001497253vivs:ProspectusToTwoThousandAndTwentyFourShelfMembervivs:AtTheMarketFacilityMember2026-03-310001497253us-gaap:RetainedEarningsMember2025-03-310001497253us-gaap:OperatingSegmentsMember2024-04-012025-03-310001497253vivs:MetacrineIncMembervivs:MetacrinesFxrProgramMember2022-04-012023-03-310001497253vivs:MetacrinesFxrProgramMembersrt:MaximumMember2024-04-012025-03-310001497253us-gaap:ProductMember2025-04-012026-03-310001497253vivs:TwoThousandAndTwentyTwoInducementEquityPlanMember2022-10-120001497253vivs:CommonWarrantsMembervivs:TwoThousandTwentySixOfferingMember2026-03-312026-03-310001497253us-gaap:TreasuryStockCommonMember2025-03-310001497253vivs:ProspectusToTwoThousandAndTwentyFourShelfMembervivs:AtTheMarketFacilityMembersrt:MaximumMember2024-01-260001497253vivs:UniversityOfMissouriMember2009-03-012009-03-310001497253vivs:PlacementAgentWarrantsMember2026-03-310001497253us-gaap:AdditionalPaidInCapitalMember2024-04-012025-03-310001497253us-gaap:MeasurementInputRiskFreeInterestRateMembervivs:CommonStockWarrantMember2026-03-310001497253us-gaap:EmployeeStockOptionMembervivs:IncentiveAwardPlanMember2026-03-310001497253us-gaap:StateAndLocalJurisdictionMember2026-03-310001497253us-gaap:GeneralAndAdministrativeExpenseMember2025-04-012026-03-310001497253vivs:MetacrineIncMembervivs:MetacrinesFxrProgramMember2024-03-310001497253vivs:TwoThousandTwentySixPre-FundedWarrantsMember2025-04-012026-03-310001497253vivs:CommonWarrantsMemberus-gaap:IPOMember2024-05-082024-05-080001497253vivs:ClemsonUniversityMember2016-03-310001497253vivs:TwoThousandTwentySixOfferingMembervivs:PlacementAgentWarrantsMember2026-03-310001497253vivs:CommonStockWarrantMember2026-03-310001497253vivs:CommonWarrantsMember2024-08-050001497253vivs:TonyLialinMember2025-08-110001497253vivs:ViscientBiosciencesMember2024-04-012025-03-310001497253us-gaap:RetainedEarningsMember2024-03-310001497253vivs:InsurancePremiumFinancingLiabilityMember2026-03-310001497253us-gaap:ProductMember2024-04-012025-03-310001497253vivs:CommonWarrantsMember2026-03-312026-03-310001497253vivs:TwoThousandAndTwentyFourCommonWarrantsMember2025-04-012026-03-310001497253vivs:TwoThousandTwentySixOfferingMember2025-04-012026-03-310001497253vivs:TwoThousandTwentyThreeEmployeeStockPurchasePlanMember2025-03-310001497253vivs:EquityIncentivePlanTwoThousandTwentyTwoMemberus-gaap:CommonStockMember2022-07-250001497253us-gaap:RetainedEarningsMember2025-04-012026-03-310001497253vivs:ClemsonUniversityMember2025-04-012026-03-310001497253vivs:EquityIncentivePlanTwoThousandTwentyTwoMembervivs:ExecutiveChairmanMembervivs:VestingCriteriaBasedOnMarketConditionsMember2024-08-052024-08-050001497253vivs:ESPPSharesMember2025-04-012026-03-310001497253vivs:ProspectusTo2021And2024ATMProspectusShelfMember2025-04-012026-03-310001497253vivs:CommonWarrantsMember2024-04-012025-03-310001497253vivs:TwoThousandAndTwentyFourShelfMember2026-03-310001497253us-gaap:RoyaltyMember2025-04-012026-03-310001497253us-gaap:SellingGeneralAndAdministrativeExpensesMember2025-04-012026-03-310001497253us-gaap:PerformanceSharesMembervivs:ExecutiveChairmanMember2024-08-052024-08-050001497253vivs:TwoThousandTwentySixOfferingMembervivs:TwoThousandAndTwentySixCommonWarrantsMember2026-03-312026-03-310001497253us-gaap:GeneralAndAdministrativeExpenseMember2024-04-012025-03-310001497253vivs:EquityIncentivePlanTwoThousandTwentyTwoMembervivs:ExecutiveChairmanMember2024-08-052024-08-050001497253us-gaap:MeasurementInputExpectedDividendRateMembervivs:PlacementAgentWarrantsMember2026-03-310001497253vivs:TwoThousandTwentySixPre-FundedWarrantsMember2026-03-310001497253vivs:MetacrinesFxrProgramMembersrt:MaximumMember2025-04-012026-03-3100014972532026-03-310001497253us-gaap:RestrictedStockUnitsRSUMembervivs:EquityIncentivePlanTwoThousandTwentyTwoMember2026-03-310001497253vivs:PreFundedWarrantMembervivs:TwoThousandTwentySixOfferingMember2026-03-312026-03-310001497253vivs:TwoThousandTwentySixPre-FundedWarrantsMembervivs:TwoThousandTwentySixOfferingMembersrt:MaximumMember2026-03-310001497253vivs:ViscientBiosciencesMember2025-04-012026-03-310001497253vivs:InsurancePremiumFinancingLiabilityMember2025-03-310001497253vivs:MetacrineIncMembervivs:MetacrinesFxrProgramMember2025-03-252025-03-250001497253vivs:MetacrineIncMembervivs:MetacrinesFxrProgramMember2025-03-250001497253vivs:CommonWarrantsMemberus-gaap:IPOMembersrt:MaximumMember2024-08-050001497253vivs:ViscientBiosciencesMember2026-03-310001497253vivs:UniversityOfMissouriMember2022-12-052022-12-050001497253us-gaap:MeasurementInputSharePriceMembervivs:PlacementAgentWarrantsMember2026-03-310001497253us-gaap:AdditionalPaidInCapitalMember2024-03-310001497253us-gaap:RestrictedStockUnitsRSUMember2025-04-012026-03-310001497253vivs:TwoThousandAndTwentyOneInducementEquityPlanMember2021-03-310001497253vivs:TwoThousandAndTwentySixCommonWarrantsMember2025-03-310001497253us-gaap:IPOMember2026-03-3100014972532025-09-300001497253vivs:PlacementAgentWarrantsMember2025-04-012026-03-310001497253us-gaap:CommonStockMember2025-03-310001497253vivs:TwoThousandTwentySixOfferingMembervivs:TwoThousandTwentySixCommonWarrantsMember2026-03-312026-03-310001497253vivs:BICOGroupABMembervivs:SalesBasedRoyaltiesMember2024-04-012025-03-310001497253vivs:ARTwoThousandTwentyTwoPlanMember2022-10-120001497253vivs:EquityIncentivePlanTwoThousandTwentyTwoMember2022-07-250001497253us-gaap:RetainedEarningsMember2026-03-310001497253us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMember2026-03-310001497253vivs:ClemsonUniversityMemberus-gaap:LicensingAgreementsMember2011-05-012011-05-310001497253vivs:SanDiegoPermanentLeaseMember2021-11-172021-11-170001497253vivs:SublicenseAgreementsMembervivs:ClemsonUniversityMember2025-04-012026-03-310001497253us-gaap:TreasuryStockCommonMember2024-03-310001497253vivs:EquityIncentivePlanTwoThousandTwentyTwoMemberus-gaap:EmployeeStockOptionMember2026-03-310001497253us-gaap:AdditionalPaidInCapitalMember2025-04-012026-03-310001497253us-gaap:RestrictedStockUnitsRSUMember2026-03-31xbrli:pureutr:sqftxbrli:sharesiso4217:USDxbrli:sharesvivs:Segmentiso4217:USDutr:Y\n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWASHINGTON, D.C. 20549\n\n \n\nFORM 10-K\n\n \n\n(Mark One)\n\n☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the Fiscal Year Ended March 31, 2026\n\nOR\n\n☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\nFor the Transition Period from to\n\nCommission File No. 001-35996\n\n \n\nVIVOSIM LABS, INC.\n\n(Exact name of registrant as specified in its charter)\n\n \n\nDelaware\n\n \n\n27-1488943\n\n(State or other jurisdiction of incorporation or organization)\n\n \n\n(IRS Employer Identification No.)\n\n \n\n \n\n \n\n11555 Sorrento Valley Rd, Suite 100\n\nSan Diego, CA\n\n \n\n92121\n\n(Address of principal executive offices)\n\n \n\n(Zip code)\n\nRegistrant’s telephone number, including area code: 858-224-1000\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\nTitle of each class\n\nTrading Symbol\n\nName of each exchange on which registered\n\nCommon Stock, par value $0.001 per share\n\nVIVS\n\nThe Nasdaq Stock Market LLC\n\nSecurities registered pursuant to section 12(g) of the Act: None\n\n \n\nIndicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒\n\nIndicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒\n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐\n\n \n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\nLarge accelerated filer\n\n☐\n\n \n\nAccelerated filer\n\n☐\n\nNon-accelerated filer\n\n☒\n\nSmaller reporting company\n\n☒\n\n \n\n \n\n \n\nEmerging growth company\n\n☐\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\nIndicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or\nissued its audit report. ☐\n\nIf securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐\n\nIndicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\nThe aggregate market value of the voting and non-voting common equity held by non-affiliates based on the closing stock price as reported on the Nasdaq Capital Market on September 30, 2025, the last trading day of the registrant’s most recently completed second fiscal quarter, was $7,538,844. For purposes of this computation only, shares of common stock held by each executive officer, director, and 10% or greater stockholders have been excluded in that such persons may be deemed affiliates.\n\nThe number of outstanding shares of the registrant’s common stock, as of July 10, 2026 was 3,494,071.\n\n \n\n \n\n \n\n \n\n \n\nVivoSim Labs, Inc.\n\nAnnual Report on Form 10-K\n\nFor the Year Ended March 31, 2026\n\nTable of Contents\n\n \n\n \n\n \n\n \n\n \n\nPage\n\n[Important Information Regarding Forward-Looking Statements](#important_information_regarding_forwardl)\n\n \n\n1\n\n \n\n \n\n \n\n \n\n \n\n[PART I](#part_i)\n\n \n\n \n\n \n\n2"}